CAS 2443767-35-7

Formula: C25H28ClN7O2S

InChI: InChI=1S/C25H28ClN7O2S/c1-33(2)11-4-12-35-19-7-8-21-22(14-19)29-16-30-23(21)27-10-9-20-15-28-25(36-20)32-24(34)31-18-6-3-5-17(26)13-18/h3,5-8,13-16H,4,9-12H2,1-2H3,(H,27,29,30)(H2,28,31,32,34)

InChI key: MMVLETOTGHDVPQ-UHFFFAOYSA-N

SMILES: CN(C)CCCOC1=CC2=C(C=C1)C(=NC=N2)NCCC3=CN=C(S3)NC(=O)NC4=CC(=CC=C4)Cl

1-(3-Chlorophenyl)-3-(5-(2-((7-(3-(Dimethylamino)Propoxy)Quinazolin-4-Yl)Amino)Ethyl)Thiazol-2-Yl)Urea

CAS: 2443767-35-7

1-(3-Chlorophenyl)-3-(5-(2-((7-(3-(Dimethylamino)Propoxy)Quinazolin-4-Yl)Amino)Ethyl)Thiazol-2-Yl)Urea

Formula: C₂₅H₂₈ClN₇O₂S

Purity: 98.45%

Molecular weight: 526.05

Ref: 54-OR1023304

BPR1K871

CAS: 2443767-35-7

BPR1K871, a preclinical development candidate for anti-cancer therapy [1], is a potent, selective dual inhibitor targeting FLT3 and AURKA, with IC50 values of

Formula: C₂₅H₂₈ClN₇O₂S

Color and Shape: Solid

Molecular weight: 526.054

Ref: TM-T10592

BPR1K871

CAS: 2443767-35-7

Formula: C₂₅H₂₈ClN₇O₂S

Purity: 98.45%

Molecular weight: 526.0535

Ref: IN-DA01TP4J

BPR1K871

CAS: 2443767-35-7

BPR1K871 is a synthetic, orally bioavailable anticancer compound that has potent anticancer activity. It is a multi-kinase inhibitor that inhibits the activity of aurora kinases A and B, AKT, ERK1/2, and JNK. BPR1K871 also inhibits the enzymatic activity of PDGFRβ kinase, which is involved in the proliferation of cancer cells. BPR1K871 has been shown to have no significant impurities and is stable in human plasma. This compound has been shown to have potent anticancer activity in preclinical studies with no toxicity to normal cells.

Formula: C₂₅H₂₈ClN₇O₂S

Purity: Min. 95%

Molecular weight: 526.1 g/mol

Ref: 3D-TXD76735